The Efficacy of Cardiac Contractility Modulation for Treating Patients with Heart Failure.

IF 1.6 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiovascular Engineering and Technology Pub Date : 2024-11-25 DOI:10.1007/s13239-024-00760-z

NingNing Zheng, YongBing Fu, MingZhu Xu, Lin Ling, TingBo Jiang, Feng Xue

{"title":"The Efficacy of Cardiac Contractility Modulation for Treating Patients with Heart Failure.","authors":"NingNing Zheng, YongBing Fu, MingZhu Xu, Lin Ling, TingBo Jiang, Feng Xue","doi":"10.1007/s13239-024-00760-z","DOIUrl":null,"url":null,"abstract":"Purpose: Heart failure (HF) is still a leading cause of mortality and morbidity despite considerable advances in therapy. This study aimed to evaluate the efficacy of cardiac contractility modulation (CCM) for treating Chinese patients with HF.Methods: This retrospective study included six HF patients who had New York Heart Association (NYHA) class II or III and received CCM implantation at the First Affiliated Hospital of Soochow University from May 2022 to May 2023. Assessments were conducted before and after 12 months of CCM treatment to evaluate the left ventricular ejection fraction (LVEF), the left ventricular end-diastolic dimension (LVEDD), the left atrium diameter (LAD), and cardiac function.Results: After the 12-month follow-up, all outcome measures showed improvement: the LVEF increased from (27 ± 4.73) % to (39.67 ± 7.06) %, the LVEDD decreased from (70.33 ± 1.97) mm to (64.83 ± 3.71) mm, and the LAD decreased from (52.83 ± 7.14) mm to (47.00 ± 7.48) mm. All patients reached NYHA functional class II.Conclusions: The findings from this small study suggest that CCM therapy can enhance the cardiac functional status, improve LVEF, and reverse ventricular remodeling.","PeriodicalId":54322,"journal":{"name":"Cardiovascular Engineering and Technology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Engineering and Technology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s13239-024-00760-z","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Heart failure (HF) is still a leading cause of mortality and morbidity despite considerable advances in therapy. This study aimed to evaluate the efficacy of cardiac contractility modulation (CCM) for treating Chinese patients with HF.

Methods: This retrospective study included six HF patients who had New York Heart Association (NYHA) class II or III and received CCM implantation at the First Affiliated Hospital of Soochow University from May 2022 to May 2023. Assessments were conducted before and after 12 months of CCM treatment to evaluate the left ventricular ejection fraction (LVEF), the left ventricular end-diastolic dimension (LVEDD), the left atrium diameter (LAD), and cardiac function.

Results: After the 12-month follow-up, all outcome measures showed improvement: the LVEF increased from (27 ± 4.73) % to (39.67 ± 7.06) %, the LVEDD decreased from (70.33 ± 1.97) mm to (64.83 ± 3.71) mm, and the LAD decreased from (52.83 ± 7.14) mm to (47.00 ± 7.48) mm. All patients reached NYHA functional class II.

Conclusions: The findings from this small study suggest that CCM therapy can enhance the cardiac functional status, improve LVEF, and reverse ventricular remodeling.

查看原文本刊更多论文

调节心肌收缩力治疗心力衰竭患者的疗效。

目的：尽管在治疗方面取得了长足进步，但心力衰竭（HF）仍是导致死亡和发病的主要原因。本研究旨在评估心脏收缩力调节（CCM）治疗中国心力衰竭患者的疗效：这项回顾性研究纳入了 6 名纽约心脏协会（NYHA）分级为 II 级或 III 级的心房颤动患者，他们于 2022 年 5 月至 2023 年 5 月期间在苏州大学附属第一医院接受了 CCM 植入术。在CCM治疗12个月前后进行评估，以评价左心室射血分数（LVEF）、左心室舒张末期尺寸（LVEDD）、左心房直径（LAD）和心功能：随访12个月后，所有结果均有所改善：LVEF从（27±4.73）%增至（39.67±7.06）%，LVEDD从（70.33±1.97）mm降至（64.83±3.71）mm，LAD从（52.83±7.14）mm降至（47.00±7.48）mm。所有患者都达到了 NYHA 功能分级 II 级：这项小型研究的结果表明，CCM疗法可以增强心脏功能状态、改善LVEF并逆转心室重塑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular Engineering and Technology Engineering-Biomedical Engineering

CiteScore

4.00

自引率

0.00%

发文量

期刊介绍： Cardiovascular Engineering and Technology is a journal publishing the spectrum of basic to translational research in all aspects of cardiovascular physiology and medical treatment. It is the forum for academic and industrial investigators to disseminate research that utilizes engineering principles and methods to advance fundamental knowledge and technological solutions related to the cardiovascular system. Manuscripts spanning from subcellular to systems level topics are invited, including but not limited to implantable medical devices, hemodynamics and tissue biomechanics, functional imaging, surgical devices, electrophysiology, tissue engineering and regenerative medicine, diagnostic instruments, transport and delivery of biologics, and sensors. In addition to manuscripts describing the original publication of research, manuscripts reviewing developments in these topics or their state-of-art are also invited.